MAP2K1 and cancer: Co is associated with thyroid cancer, and inhibition of MEK1/2 kinase activity by Co chelating agents may be used in combination with other MAPK pathway inhibitors to treat BRAF mutation-positive cancers and cancers resistant to BRAFV600E and MEK1/2 inhibitors (102).